BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 9530372)

  • 1. [Paclitaxel (taxol): a review of its antitumor activity and toxicity in clinical studies].
    Yamazaki S; Sekine I; Saijo N
    Gan To Kagaku Ryoho; 1998 Mar; 25(4):605-15. PubMed ID: 9530372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paclitaxel (Taxol): a review of its antitumor activity in clinical studies Minireview.
    Hájek R; Vorlicek J; Slavik M
    Neoplasma; 1996; 43(3):141-54. PubMed ID: 8841500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Paclitaxel (Taxol)].
    Hájek R
    Cas Lek Cesk; 1996 Jun; 135(12):393-6. PubMed ID: 8706079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacological action of paclitaxel].
    Potemski P; Płuzańska A
    Pol Merkur Lekarski; 1999 Jan; 6(31):27-9. PubMed ID: 10344150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paclitaxel: a new antineoplastic agent for refractory ovarian cancer.
    Gregory RE; DeLisa AF
    Clin Pharm; 1993 Jun; 12(6):401-15. PubMed ID: 7691462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of dose-escalated paclitaxel, ifosfamide, and cisplatin (PIC) combination chemotherapy in advanced solid tumours.
    Kosmas C; Tsavaris NB; Polyzos A; Malamos NA; Katsikas M; Antonopoulos MJ
    Br J Cancer; 2000 Jan; 82(2):300-7. PubMed ID: 10646881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with paclitaxel alone rather than combination with paclitaxel and cisplatin may be selective for cisplatin-resistant ovarian carcinoma.
    Yamamoto K; Kikuchi Y; Kudoh K; Hirata J; Kita T; Nagata I
    Jpn J Clin Oncol; 2000 Oct; 30(10):446-9. PubMed ID: 11185891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multi-center study of two dose levels of paclitaxel with carboplatin in locally advanced and metastatic non-small cell lung cancer (NSCLC).
    Glorieux P; Ortmanns P; Marien S; Degives R; Degraeve D; Potvin M; Grauwels D; Schallier D
    Anticancer Res; 2001; 21(2B):1487-94. PubMed ID: 11396237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paclitaxel pharmacology and other tumor types.
    Rowinsky EK
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-1-S19-12. PubMed ID: 9427257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Experience in first-line chemotherapy with paclitaxel for the treatment of ovarian carcinomas].
    Pete I; Szánthó A; Mayer A; Thurzó L; Pulay T
    Orv Hetil; 2003 May; 144(19):919-24. PubMed ID: 12809068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paclitaxel (Taxol)/carboplatin combination chemotherapy in the treatment of advanced ovarian cancer.
    Ozols RF
    Semin Oncol; 2000 Jun; 27(3 Suppl 7):3-7. PubMed ID: 10952119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Advanced cancer of the ovary. The paclitaxel-cisplatin combination as the first-line standard of treatment].
    Pecorelli S
    Recenti Prog Med; 1999 Jun; 90(6):338-41. PubMed ID: 10399475
    [No Abstract]   [Full Text] [Related]  

  • 14. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial.
    Markman M; Liu PY; Wilczynski S; Monk B; Copeland LJ; Alvarez RD; Jiang C; Alberts D; ;
    J Clin Oncol; 2003 Jul; 21(13):2460-5. PubMed ID: 12829663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of paclitaxel (taxol), cisplatin, and the combination paclitaxel-cisplatin in ovarian cancer in vitro with the ATP cell viability assay.
    Untch M; Sevin BU; Perras JP; Angioli R; Untch A; Hightower RD; Koechli O; Averette HE
    Gynecol Oncol; 1994 Apr; 53(1):44-9. PubMed ID: 7909786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
    Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
    Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Taxol: an important new drug in the management of epithelial ovarian cancer.
    Markman M
    Yale J Biol Med; 1991; 64(6):583-90. PubMed ID: 1687343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies.
    Chaudhry V; Rowinsky EK; Sartorius SE; Donehower RC; Cornblath DR
    Ann Neurol; 1994 Mar; 35(3):304-11. PubMed ID: 7907208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma.
    Kim YH; Shin SW; Kim BS; Kim JH; Kim JG; Mok YJ; Kim CS; Rhyu HS; Hyun JH; Kim JS
    Cancer; 1999 Jan; 85(2):295-301. PubMed ID: 10023695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel in head and neck and other cancers: future prospects.
    Aisner J; Cortés-Funes H
    Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-113-S2-115. PubMed ID: 9045328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.